Detail

Study ID: Abbott XIENCE 28 ABT-CIP-10271 USA Study

Title:

XIENCE 28 USA Study

Description:
Title: Abbott XIENCE 28 USA Study Description: The XIENCE Short DAPT study is designed to evaluate the safety of taking two types of blood thinning drugs (also known as antiplatelet drugs) for 28 days after the implantation of any commercially approved XIENCE stents for patients at high risk of bleeding. The XIENCE stent is not being investigated in this study, nor are the antiplatelet drugs. The study will gather information on the dual use of a P2Y12 inhibitor (antiplatelet drug) for a short period of time (28 days) along with the indefinite use (no time limit) of aspirin (antiplatelet drug) for patients receiving XIENCE stents. To understand the long-term success of dual antiplatelet therapy in reducing the incidents of severe bleeding, study participants will need to return for a few visits during the first 12 months of the study. All data collected at the end of the study will be used to support a dual antiplatelet therapy following a cardiac stent procedure.
Location:
Sioux Falls Region
Principal Investigator:
Tomasz Stys, MD
Disease:
Heart
Stage:
IDE
Status:
Active - Open to Accrual